

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000800

International filing date: 04 March 2005 (04.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0412261.0
Filing date: 02 June 2004 (02.06.2004)

Date of receipt at the International Bureau: 07 April 2005 (07.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



GB 05/800



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 21 March 2005





03JUN04 E900591-2 001631
P01/7740 0.00-0412261.0 NONE

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

Fee: £

1. Your reference	47627.GB02/NT	- 2 JUN 2004	
2. Patent application number (The Patent Office will fill in this part)	0412261.0		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	Cambridge Biotechnology Ltd P.O. Box 230 Cambridge CB2 1XJ United Kingdom		
Patents ADP number (if you know it)			
If the applicant is a corporate body, give the country/state of incorporation	United Kingdom		
4. Title of the invention	Analgesics		
5. Full name, address and postcode in the United Kingdom to which all correspondence relating to this form and translation should be sent	Reddie & Grose 16 Theobalds Road LONDON WC1X 8PL		
Patents ADP number (if you know it)	91001		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application (If you know it)	Date of filing (day/month/year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day/month/year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	Yes		

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document.

Continuation sheets of this form -

Description 16

Claim(s) 6

Abstract -

Drawing(s) -



10. If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents -

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*) -

Request for preliminary examination and search (*Patents Form 9/77*) -

Request for substantive examination (*Patents Form 10/77*) -

Any other documents (*please specify*) -

11. I/We request the grant of a patent on the basis of this application.

Signature(s) *Peddie & Goose*

Date 1 June 2004

12. Name and daytime telephone number of person to contact in the United Kingdom

N THORNTON
01223 -360 650

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Analgesics

This invention relates to analgesic compounds and to methods of preventing, treating, or ameliorating pain using these compounds.

Pain has two components, each involving activation of sensory neurons. The first component is the early or immediate phase when a sensory neuron is stimulated, for instance as the result of heat or pressure on the skin. The second component is the consequence of an increased sensitivity of the sensory mechanisms innervating tissue which has been previously damaged. This second component is referred to as hyperalgesia, and is involved in all forms of chronic pain arising from tissue damage, but not in the early or immediate phase of pain perception.


Thus, hyperalgesia is a condition of heightened pain perception caused by tissue damage. This condition is a natural response of the nervous system apparently designed to encourage protection of the damaged tissue by an injured individual, to give time for tissue repair to occur. There are two known underlying causes of this condition, an increase in sensory neuron activity, and a change in neuronal processing of nociceptive information which occurs in the spinal cord. Hyperalgesia can be debilitating in conditions of chronic inflammation (e.g. rheumatoid arthritis), and when sensory nerve damage has occurred (i.e. neuropathic pain).

Two major classes of analgesics are known: (i) non steroidal anti-inflammatory drugs (NSAIDs) and the related COX-2 inhibitors; and (ii) opiates based on morphine. Analgesics of both classes are effective in controlling normal, immediate or nociceptive pain. However, they are less effective against some types of hyperalgesic pain, such as neuropathic pain. Many medical practitioners are reluctant to prescribe opiates at the high doses required to affect neuropathic pain because of the side effects caused by administration of these compounds, and the possibility that patients may become addicted to them. NSAIDs are much less potent than opiates, so even higher doses of these compounds are required. However, this is undesirable because these compounds cause irritation of the gastro-intestinal tract.

Adenosine A1 receptor agonists are known to act as powerful analgesics (Sawynok, Eur J Pharmacol. (1998) 347, 1-11), and adenosine A2A receptor agonists are known to act as anti-inflammatory agents. However, development of adenosine-based therapies has generally been precluded because they have unacceptable side effects. Selective A1 receptor agonists cause bradycardia, and A2A receptor agonists cause widespread vasodilation with consequent hypotension and tachycardia.

There is, therefore, a need to provide analgesics, particularly anti-hyperalgesics, which are sufficiently potent to control pain perception in neuropathic and other hyperalgesic syndromes, and which do not have serious side effects or cause patients to become addicted to them.

According to the invention there is provided adenosine receptor agonists of the following formulae:




(I)

wherein:


when $\text{X} = \text{OH}$, R_1 is C_1 or $\text{C}_4\text{-C}_6$ alkoxy, phenoxy, substituted phenoxy (preferably substituted with nitrile, phenyl or 3-isopropyl), (5-indanyl)oxy, C_1 , C_2 , C_5 , or C_6 alkylamino (straight chain or cyclic), phenylamino, phenylamino with either methoxy or fluoro substituents, (N-methyl, N-isoamylamino), a C_2 sulfone group, a C_7 alkyl group, or $\text{OCH}_2\text{CH}_2\text{OH}$; or

when $X = H$, R_1 is *n*-hexyloxy;



(II)

wherein R_2 is NMe_2 , N -(2-isopentenyl), piperazinyl, (N-Me, N-benzyl) or (N-Me, N-(2-methoxyethyl));




(III)

wherein:

when $R_1 = H$, R_3 is an isopropyl group, and R_2 is either NH_2 or a methylamino group ($NHMe$); or

when $R_1 = H$, R_3 is H , and R_2 is NH_2 ; or
when R_1 is OMe , R_3 is Ph , and R_2 is NH_2 ;



(IV)

wherein R_4 is *n*-propyl or $NHCH_2CH_3$.

It is believed that compounds of formulae (I)-(IV) have analgesic activity and can be administered with reduced probability and severity of side effects compared to other adenosine receptor agonists:

According to the invention there is provided use of a compound of formula (I), (II), (III), or (IV) in the manufacture of a medicament for the prevention, treatment, or amelioration of pain, particularly hyperalgesia.

There is also provided according to the invention a method of preventing, treating, or ameliorating pain (particularly hyperalgesia) which comprises administering a compound of formula (I), (II), (III), or (IV) to a subject in need of such prevention, treatment, or amelioration.

Preferred compounds of formula (I), (II), (III), and (IV) are detailed in the Examples.

Compounds of formulae (I)-(IV) are believed to be effective in inhibiting pain perception in mammals suffering from pain, in particular neuropathic or inflammatory pain, even when administered at doses expected to give plasma concentrations well below those known to activate adenosine receptors. Therefore, it is believed that compounds of formulae (I)-(IV) can treat pain (particularly neuropathic and inflammatory pain) without causing the significant side effects associated with administration of other adenosine receptor agonists.

As mentioned above hyperalgesia is a consequence in most instances of tissue damage, either damage directly to a sensory nerve, or damage of the tissue innervated by a given sensory nerve. Consequently, there are many conditions in which pain perception includes a component of hyperalgesia.

According to the invention there is provided use of a compound of formula (I), (II), (III), or (IV) as an analgesic (particularly an anti-hyperalgesic) for the prevention, treatment, or amelioration of pain (particularly hyperalgesia) caused as a result of neuropathy, including Diabetic Neuropathy, Polyneuropathy, Cancer Pain, Fibromyalgia, Myofascial Pain Syndrome, Osteoarthritis, Pancreatic Pain, Pelvic/Perineal pain, Post Herpetic Neuralgia, Rheumatoid Arthritis, Sciatica/Lumbar Radiculopathy, Spinal Stenosis, Temporo-mandibular Joint Disorder, HIV pain, Trigeminal Neuralgia, Chronic Neuropathic Pain, Lower Back Pain, Failed Back Surgery pain, back pain, post-operative pain, post physical trauma pain (including gunshot, road traffic accident, burns), Cardiac pain, Chest pain, Pelvic pain/PID, Joint pain (tendonitis, bursitis, acute arthritis), Neck Pain, Bowel Pain, Phantom Limb Pain, Obstetric Pain (labour/C-Section), Renal Colic, Acute Herpes Zoster Pain, Acute Pancreatitis Breakthrough Pain (Cancer), Dysmenorrhoea/Endometriosis.

According to the invention there is also provided use of a compound of formula (I), (II), (III), or (IV) as an analgesic (particularly an anti-hyperalgesic) for the prevention, treatment, or amelioration of pain (particularly hyperalgesia) caused as a result of inflammatory disease, or as a result of combined inflammatory, autoimmune and neuropathic tissue damage, including rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis, and other arthritic conditions, cancer, HIV, chronic

pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption diseases, reperfusion injury (including damage caused to organs as a consequence of reperfusion following ischaemic episodes e.g. myocardial infarcts, strokes), autoimmune damage (including multiple sclerosis, Guillam Barre Syndrome, myasthenia gravis) graft v. host rejection, allograft rejections, fever and myalgia due to infection, AIDS related complex (ARC), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis and pyresis, irritable bowel syndrome, osteoporosis, cerebral malaria and bacterial meningitis, bowel pain, cancer pain, back pain, fibromyalgia, post-operative pain.

It has also been appreciated that compounds of formula (I)-(IV) may be effective in the prevention, treatment, or amelioration of ischaemic pain.

The term "ischaemic pain" is used herein to mean pain associated with a reduction in blood supply to a part of the body. A reduced blood supply limits the supply of oxygen (hypoxia) and energy to that part of the body. Ischaemia arises from poor blood perfusion of tissues and so ischaemic pain arises in coronary artery disease, peripheral artery disease, and conditions which are characterized by insufficient blood flow, usually secondary to atherosclerosis. Other vascular disorders can also result in ischaemic pain. These include: left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncope, arteriosclerosis, mild chronic heart failure, angina pectoris, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis obliterans), arteritis, diastolic dysfunction and systolic dysfunction, atherosclerosis, post ischaemia/reperfusion injury, diabetes (both Types I and II), thromboembolisms. Haemorrhagic accidents can also result in ischaemic pain. In addition poor perfusion can result in neuropathic and inflammatory pain arising from hypoxia-induced nerve cell damage (e.g. in cardiac arrest or bypass operation, diabetes or neonatal distress).

The amount of a compound of the invention that is administered to a subject should be an amount which gives rise to a peak plasma concentration that is less than the

lowest EC50 value of the compound at adenosine receptors (i.e. less than the lowest EC50 value of the compound at A1, A2A, A2B, and A3 adenosine receptors). Preferably the peak plasma concentration of the compound is one ten thousandth to one fifth (or one ten thousandth to one twentieth, or one ten thousandth to one hundredth, or one ten thousandth to one thousandth, or one thousandth to one fifth, or one thousandth to one twentieth, or one fiftieth to one tenth, or one hundredth to one fifth, or one fiftieth to one fifth, or one tenth to one fifth) of the lowest EC50 value.

Preferably the amount of a compound of the invention that is administered gives rise to a plasma concentration that is maintained for more than one hour at one ten thousandth to one fifth (or one ten thousandth to one twentieth, or one ten thousandth to one hundredth, or one ten thousandth to one thousandth, or one thousandth to one fifth, or one thousandth to one twentieth, or one fiftieth to one tenth, or one hundredth to one fifth, or one fiftieth to one fifth, or one tenth to one fifth) of the lowest EC50 value of the compound at adenosine receptors.

For the avoidance of doubt, the EC50 value of a compound is defined herein as the concentration of the compound that provokes a receptor response halfway between the baseline receptor response and the maximum receptor response (as determined, for example, using a dose-response curve).

The EC50 value should be determined under standard conditions (balanced salt solutions buffered to pH 7.4). For EC50 determinations using isolated membranes, cells and tissues this would be in buffered salt solution at pH 7.4 (e.g. cell culture medium), for example as in Tilburg *et al* (J. Med. Chem. (2002) 45, 91-100). The EC50 could also be determined *in vivo* by measuring adenosine receptor mediated responses in a normal healthy animal, or even in a tissue perfused under normal conditions (i.e. oxygenated blood, or oxygenated isotonic media, also buffered at pH 7.4) in a normal healthy animal.

Alternatively, the amount of a compound of the invention that is administered may be an amount that results in a peak plasma concentration that is less than the lowest or highest Kd value of the compound at adenosine receptors (i.e. less than the lowest or

highest K_d value of the compound at A1, A2A, A2B, and A3 adenosine receptors). Preferably the peak plasma concentration of the compound is one ten thousandth to one fifth (or one ten thousandth to one twentieth, or one ten thousandth to one hundredth, or one ten thousandth to one thousandth, or one thousandth to one fifth, or one thousandth to one twentieth, or one fiftieth to one tenth, or one hundredth to one fifth, or one fiftieth to one fifth, or one tenth to one fifth) of the lowest or highest K_d value.

Preferably the amount of the compound that is administered is an amount that results in a plasma concentration that is maintained for more than one hour at one ten thousandth to one fifth (or one ten thousandth to one twentieth, or one ten thousandth to one hundredth, or one ten thousandth to one thousandth, or one thousandth to one fifth, or one thousandth to one twentieth, or one fiftieth to one tenth, or one hundredth to one fifth, or one fiftieth to one fifth, or one tenth to one fifth) of the lowest or highest K_d value of the compound at adenosine receptors.

The K_d value of the compound at each receptor should be determined under standard conditions using plasma membranes as a source of the adenosine receptors derived either from tissues or cells endogenously expressing these receptors or from cells transfected with DNA vectors encoding the adenosine receptor genes. Alternatively whole cell preparations using cells expressing adenosine receptors can be used. Labelled ligands (e.g. radiolabelled) selective for the different receptors should be used in buffered (pH7.4) salt solutions (see e.g. Tilburg et al, J. Med. Chem. (2002) 45, 420-429) to determine the binding affinity and thus the K_d of the compound at each receptor.

Alternatively, the amount of a compound of the invention that is administered may be an amount that is one ten thousandth to one fifth (or one ten thousandth to one twentieth, or one ten thousandth to one hundredth, or one ten thousandth to one thousandth, or one thousandth to one fifth, or one thousandth to one twentieth, or one fiftieth to one tenth, or one hundredth to one fifth, or one fiftieth to one fifth, or one tenth to one fifth) of the minimum amount of the compound that gives rise to bradycardia, hypotension or tachycardia side effects in animals of the same species as

the subject to which the compound is to be administered. Preferably the amount administered gives rise to a plasma concentration that is maintained for more than one hour at one ten thousandth to one fifth (or one ten thousandth to one twentieth, or one ten thousandth to one hundredth, or one ten thousandth to one thousandth, or one thousandth to one fifth, or one thousandth to one twentieth, or one fiftieth to one tenth, or one hundredth to one fifth, or one fiftieth to one fifth, or one tenth to one fifth) of the minimum amount of the compound that gives rise to the side effects.

Alternatively, the amount of a compound of the invention that is administered may be an amount that gives rise to plasma concentrations that are one ten thousandth to one fifth (or one ten thousandth to one twentieth, or one ten thousandth to one hundredth, or one ten thousandth to one thousandth, or one thousandth to one fifth, or one thousandth to one twentieth, or one fiftieth to one tenth, or one hundredth to one fifth, or one fiftieth to one fifth, or one tenth to one fifth) of the minimum plasma concentration of the compound that cause bradycardia, hypotension or tachycardia side effects in animals of the same species as the subject to which the compound is to be administered. Preferably the amount administered gives rise to a plasma concentration that is maintained for more than one hour at one ten thousandth to one fifth (or one ten thousandth to one twentieth, or one ten thousandth to one hundredth, or one ten thousandth to one thousandth, or one thousandth to one fifth, or one thousandth to one twentieth, or one fiftieth to one tenth, or one hundredth to one fifth, or one fiftieth to one fifth, or one tenth to one fifth) of the minimum plasma concentration of the compound that causes the side effects.

It is expected that the amount of a compound of the invention that is administered should be 0.001-15 mg/kg. The amount may be less than 6 mg/kg. The amount may be at least 0.001, 0.01, or 0.1 mg/kg. The amount may be less than 0.1, or 0.01 mg/kg. Preferred ranges are 0.001-10, 0.001-5, 0.001-2, 0.001-1, 0.001-0.1, 0.001-0.01, 0.01-10, 0.01-5, 0.01-2, 0.01-1, 0.1-10, 0.1-5, 0.1-2, 0.1-1, 0.2-1.2, 0.2-1, mg/kg.

Preferred doses for a 70kg human subject are less than 420mg, preferably at least 0.7mg, more preferably at least 3.5mg, most preferably at least 7mg. More preferably 7-70mg, or 14-70mg.

It is believed that the dosage amounts specified above are significantly lower (up to approximately 1000 times lower) than would be expected to be required for an analgesic effect based on the EC50 value of the compound at the adenosine A2A receptor.

The appropriate dosage of a compound of the invention will vary with the age, sex, weight, and condition of the subject being treated, the potency of the compound, and the route of administration, etc. The appropriate dosage can readily be determined by one skilled in the art.

A compound of the invention may be administered with or without other therapeutic agents, for example analgesics or anti-inflammatories (such as opiates, steroids, NSAIDs, cannabinoids, tachykinin modulators, or bradykinin modulators) or anti-hyperalgesics (such as gabapentin, pregabalin, cannabinoids, sodium or calcium channel modulators, anti-epileptics or anti-depressants).

In general, a compound of the invention may be administered by known means, in any suitable formulation, by any suitable route. A compound of the invention is preferably administered orally, parenterally, sublingually, transdermally, intrathecally, or transmucosally. Other suitable routes include intravenous, intramuscular, subcutaneous, inhaled, and topical. The amount of drug administered will typically be higher when administered orally than when administered, say, intravenously.

It will be appreciated that a compound of the invention may be administered together with a physiologically acceptable carrier, excipient, or diluent.


Suitable compositions, for example for oral administration, include solid unit dose forms, and those containing liquid, e.g. for injection, such as tablets, capsules, vials and ampoules, in which the active agent is formulated, by known means, with a physiologically acceptable excipient, diluent or carrier. Suitable diluents and carriers are known, and include, for example, lactose and talc, together with appropriate binding agents etc.

A unit dosage of a compound of the invention typically comprises up to 500 mg (for example 1 to 500 mg, preferably 5 to 500 mg) of the active agent. Preferably the active agent is in the form of a pharmaceutical composition comprising the active agent and a physiologically acceptable carrier, excipient, or diluent. The preferred dosage is 0.1 to 2, e.g. 0.5 to 1, typically about 0.2 or 0.6, mg of the active agent per kg of the (human) subject. At these levels, it is believed that effective treatment can be achieved substantially without a concomitant fall (for example, no more than 10%) in blood pressure.

Preferably a compound of the invention is administered at a frequency of 2 or 3 times per day.

Structures of preferred compounds of the invention are given in the Examples below. A K_i value is given for each compound. To calculate this, rat striatal membranes were incubated for 90 minutes at 22°C in the presence of 2nM [3H]-CGS21680, 1Unit/ml adenosine deaminase and increasing concentrations of the compound being studied, prior to filtration and liquid scintillation counting.

Example 1



When X = OH


Compound No.	Structure R ₁	(K _i) nM
1	OCH ₃	1300
2	OCH ₂ CH ₂ CH ₂ CH ₃	280
3	O CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH ₃	1500
4	OPh	2500
5	O-(4-cyano)Ph	1300
6	O-(3-Ph)Ph	620
7	5-indanyloxy	760
8	O-(3-CH(CH ₃) ₂)Ph	560
9	NH(CH ₃)	1356
10	NHCH ₂ CH ₃	1200
11	N(CH ₃) ₂	13350
12	NHCH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH ₃	290
13	NHPh	160
14	NH-(4-MeO)Ph	55
15	NH-(4-F)Ph	200
16	NH-cyclopentyl	420
17	NH-cyclohexyl	1000

18	N-CH ₃ , N-CH ₂ CH ₂ CH(CH ₃) ₂	4000
19	OCH ₂ cyclopentyl	200
20	SO ₂ CH ₂ CH ₃	39000
21	OCH ₂ CH ₂ OH	203
22	CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH ₃	800

When X = H


Compound No.	Structure R ₁	(K _i) nM
23	O CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH ₃	2990

Example 2




Compound No.	Structure R_2	(K_i) nM
24	$N(CH_3)_2$	450000
25	$NHCH_2CHC(CH_3)_2$	8600
26	N- CH_3 , N- CH_2Ph	18500
27	Piperazinyl	5000
28	N-Me, N-($CH_2CH_2OCH_3$)	13000

Example 3



Compound No.	R ₁	R ₂	R ₃	(K _i) nM
29	H	NH ₂	CH(CH ₃) ₂	1930
30	H	NH ₂	H	270
31	H	NHCH ₃	CH(CH ₃) ₂	2440
32	OCH ₃	NH ₂	Ph	26100


Example 4



Compound No.	Structure R_4	(Ki) nM
33	$\text{CH}_2\text{CH}_2\text{CH}_3$	16900
34	NHCH_2CH_3	6570

Claims

1. A compound of formula (I), (II), (III), or (IV):




(I)

wherein:


when $\text{X} = \text{OH}$, R_1 is C_1 or $\text{C}_4\text{-C}_6$ alkoxy, phenoxy, substituted phenoxy (preferably substituted with nitrile, phenyl or 3-isopropyl), (5-indanyl)oxy, C_1 , C_2 , C_5 , or C_6 alkylamino (straight chain or cyclic), phenylamino, phenylamino with either methoxy or fluoro substituents, (N-methyl, N-isoamylamino), a C_2 sulfone group, a C_7 alkyl group, or $\text{OCH}_2\text{CH}_2\text{OH}$; or

when $\text{X} = \text{H}$, R_1 is *n*-hexyloxy;



(II)

wherein R_2 is NMe_2 , N -(2-isopentenyl), piperazinyl, (N-Me, N-benzyl) or (N-Me, N-(2-methoxyethyl));




(III)

wherein:

when $R_1 = H$, R_3 is an isopropyl group, and R_2 is either NH_2 or a methylamino group ($NHMe$); or

when $R_1 = H$, R_3 is H , and R_2 is NH_2 ; or

when R_1 is OMe , R_3 is Ph , and R_2 is NH_2 ;



(IV)

wherein R_4 is *n*-propyl or $NHCH_2CH_3$.

2. A compound according to claim 1 with a structure as defined in any of Examples 1-4.
3. A compound according to claim 1 or 2 for use as a medicament.
4. Use of a compound according to claim 1 or 2 in the manufacture of a medicament for the prevention, treatment, or amelioration of pain.
5. Use according to claim 4, wherein the pain is hyperalgesia.
6. Use according to claim 5, wherein the hyperalgesia is neuropathic pain.
7. Use according to any of claims 4 to 6 for the prevention, treatment, or amelioration of: pain associated with cancer, pancreatic pain, pelvic/perineal pain, pain associated with HIV infection, chronic neuropathic pain, lower back pain, failed back surgery pain, back pain, post-operative pain, post physical trauma pain, cardiac pain, chest pain, pelvic pain/PID, joint pain, neck pain, bowel pain, phantom limb pain, obstetric pain, acute herpes zoster pain, acute pancreatitis breakthrough pain, or for the prevention, treatment, or amelioration of neuropathic or other pain caused by,

or associated with diabetic neuropathy, polyneuropathy, fibromyalgia, myofascial pain syndrome, osteoarthritis, post herpetic neuralgia, rheumatoid arthritis, sciatica/lumbar radiculopathy, spinal stenosis, temporo-mandibular joint disorder, trigeminal neuralgia, renal colic, dysmenorrhoea/endometriosis.

8. Use according to claim 5, wherein the hyperalgesia is inflammatory pain.

9. Use according to any of claims 4, 5, or 8 wherein the pain is caused by or associated with an inflammatory or immune disease, or as a result of combined inflammatory, autoimmune and neuropathic tissue damage.

10. Use according to any of claims 4, 5, 8, or 9 for the prevention, treatment, or amelioration of bowel pain, pain associated with cancer, back pain, post-operative pain, or for the prevention, treatment, or amelioration of inflammatory or other pain caused by, or associated with rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis, cancer, HIV, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption diseases, reperfusion injury, autoimmune damage, graft v. host rejection, allograft rejections, fever and myalgia due to infection, fibromyalgia, AIDS related complex (ARC), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis and pyresis, irritable bowel syndrome, osteoporosis, cerebral malaria and bacterial meningitis.

11. Use according to claim 4 in the manufacture of a medicament for the prevention, treatment, or amelioration of ischaemic pain.

12. Use according to claim 4 or 11 in the manufacture of a medicament for the prevention, treatment, or amelioration of pain associated with coronary artery disease, peripheral artery disease, left ventricular hypertrophy, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncope, arteriosclerosis, mild chronic heart failure, angina pectoris, Prinzmetal's (variant) angina, stable angina, exercise induced angina, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis obliterans), arteritis, diastolic dysfunction, systolic dysfunction,

atherosclerosis, post ischaemia/reperfusion injury, diabetes (Types I or II), thromboembolisms, haemorrhagic accidents, or neuropathic or inflammatory pain arising from hypoxia-induced nerve cell damage.

13. A method of preventing, treating, or ameliorating pain which comprises administering a compound according to claim 1 or 2 to a subject in need of such prevention, treatment, or amelioration.

14. A method according to claim 13, wherein the compound is administered to the subject in an amount that results in a peak plasma concentration of the compound in the subject that is one ten thousandth to one fifth of the lowest EC50 value of the compound at adenosine receptors.

15. A method according to claim 13 or 14, wherein the compound is administered to the subject in an amount that results in a plasma concentration of the compound in the subject being maintained for more than one hour at one ten thousandth to one fifth of the lowest EC50 value of the compound at adenosine receptors.

16. A method according to any of claims 13 to 15, wherein the compound is administered to the subject in an amount that results in a peak plasma concentration of the compound in the subject that is one ten thousandth to one fifth of the lowest Kd value of the compound at adenosine receptors.

17. A method according to any of claims 13 to 16, wherein the compound is administered to the subject in an amount that results in a plasma concentration of the compound in the subject being maintained for more than one hour at one ten thousandth to one fifth of the lowest Kd value of the compound at adenosine receptors.

18. A method according to any of claims 13 to 17, wherein the compound is administered to the subject in an amount that is one ten thousandth to one fifth of the minimum amount of the compound that gives rise to bradycardia, hypotension or

tachycardia side effects in animals of the same species as the subject to which the compound is administered.

19. A method according to any of claims 13 to 18, wherein the compound is administered to the subject in an amount that results in a plasma concentration of the compound in the subject being maintained for more than one hour at one ten thousandth to one fifth of the minimum plasma concentration of the compound that gives rise to bradycardia, hypotension or tachycardia side effects in animals of the same species as the subject to which the compound is administered.

20. A method according to any of claims 13 to 19, wherein the compound is administered at a dosage of 0.001 to 6 mg/kg.





100